sacituzumab govitecan and other adcs in prostate cancer
Published 7 months ago • 73 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
1:11
using sacituzumab govitecan and other adcs in urothelial cancers
-
1:58
ascent-04: sacituzumab govitecan and pembrolizumab in pd-l1-positive tnbc
-
1:49
final os analysis of sacituzumab govitecan in tropics-02
-
1:08
ascent-05: sacituzumab govitecan and pembrolizumab in tnbc
-
4:25
ascent: sacituzumab govitecan shows promise in mtnbc patients
-
1:36
real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer
-
2:57
efficacy of sacituzumab govitecan in muc by trop-2 expression
-
1:34
sacituzumab govitecan effective for hr metastatic breast cancer regardless of trop-2 status
-
2:38
trophy-u-01 cohort 3: sacituzumab govitecan pembrolizumab for patients with muc
-
2:02
sacituzumab govitecan in the treatment of metastatic urothelial carcinoma
-
2:16
efficacy of sacituzumab govitecan by trop-2 expression in patients with muc
-
0:52
dad trial: combining sacituzumab govitecan and ev for the treatment of bladder cancer
-
2:15
ascent: sacituzumab govitecan biomarker analysis
-
6:01
sacituzumab govitecan given accelerated fda approval for advanced urothelial cancer
-
3:53
sacituzumab govitecan in metastatic urothelial carcinoma: updates on the phase ii study
-
6:17
antibody-drug conjugates in tnbc: sacituzumab govitecan
-
5:01
sacituzumab govitecan in patients with previously treated muc
-
1:59
enfortumab vedotin as monotherapy in heavily pretreated mcrpc
-
1:05
future endeavours with adcs in bladder cancer